User login
Dr. Lorraine L. Rosamilia of the department of dermatology at Geisinger Health System in State College, Pa., shared her views on new data regarding topical treatments for onychomycosis with Dermatology News’ sister publication, Cutis, remarking, “Do you agree that nary a day goes by without an e-mailed article or continuing medical education opportunity tasked at ‘getting to know’ new topical onychomycosis therapies? That being said, how often have you summarily deleted them, assuming that topicals just don’t work? I know I have.” But these treatments deserve some attention, she said, based on her review of an article published in the Journal of Clinical and Aesthetic Dermatology (2014;7:10-8). Based on those data, she said, “perhaps these medications, particularly efinaconazole, at least deserve perusal compared to our current meager topical and systemic options.”
Dr. Rosamilia had no financial conflicts to disclose.
Dr. Lorraine L. Rosamilia of the department of dermatology at Geisinger Health System in State College, Pa., shared her views on new data regarding topical treatments for onychomycosis with Dermatology News’ sister publication, Cutis, remarking, “Do you agree that nary a day goes by without an e-mailed article or continuing medical education opportunity tasked at ‘getting to know’ new topical onychomycosis therapies? That being said, how often have you summarily deleted them, assuming that topicals just don’t work? I know I have.” But these treatments deserve some attention, she said, based on her review of an article published in the Journal of Clinical and Aesthetic Dermatology (2014;7:10-8). Based on those data, she said, “perhaps these medications, particularly efinaconazole, at least deserve perusal compared to our current meager topical and systemic options.”
Dr. Rosamilia had no financial conflicts to disclose.
Dr. Lorraine L. Rosamilia of the department of dermatology at Geisinger Health System in State College, Pa., shared her views on new data regarding topical treatments for onychomycosis with Dermatology News’ sister publication, Cutis, remarking, “Do you agree that nary a day goes by without an e-mailed article or continuing medical education opportunity tasked at ‘getting to know’ new topical onychomycosis therapies? That being said, how often have you summarily deleted them, assuming that topicals just don’t work? I know I have.” But these treatments deserve some attention, she said, based on her review of an article published in the Journal of Clinical and Aesthetic Dermatology (2014;7:10-8). Based on those data, she said, “perhaps these medications, particularly efinaconazole, at least deserve perusal compared to our current meager topical and systemic options.”
Dr. Rosamilia had no financial conflicts to disclose.